98 related articles for article (PubMed ID: 24850608)
1. Evaluation of state opioid substitution treatment program in Georgia.
Piralishvili G; Chavchanidze M; Gamkrelidze I; Nikolaishvili N
Georgian Med News; 2014 Apr; (229):62-6. PubMed ID: 24850608
[TBL] [Abstract][Full Text] [Related]
2. Needs assessment and treatment compliance at state opioid substitution treatment programes in Georgia.
Piralishvili G; Gamkrelidze I; Nikolaishvili N; Chavchanidze M
Georgian Med News; 2013 Jan; (214):28-32. PubMed ID: 23388531
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the quality of life (Whoqol-Bref) among methadone and suboxone substitution state program patients and healthy volunteers in Georgia.
Piralishvili G; Gamkrelidze I; Nikolaishvili N; Chavchanidze M
Georgian Med News; 2012 Dec; (213):44-7. PubMed ID: 23293233
[TBL] [Abstract][Full Text] [Related]
4. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
[TBL] [Abstract][Full Text] [Related]
5. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
7. Retention in Georgia opioid substitution therapy program and associated factors.
Ruadze E; Todadze K
Harm Reduct J; 2016 Dec; 13(1):35. PubMed ID: 27931232
[TBL] [Abstract][Full Text] [Related]
8. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
9. Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study.
Ayres R; Ingram J; Rees A; Neale J; Beattie A; Telfer M
Subst Abuse Treat Prev Policy; 2014 Nov; 9():44. PubMed ID: 25407020
[TBL] [Abstract][Full Text] [Related]
10. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
[TBL] [Abstract][Full Text] [Related]
11. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
Johnson B; Richert T
Int J Drug Policy; 2015 Feb; 26(2):183-90. PubMed ID: 25465344
[TBL] [Abstract][Full Text] [Related]
12. Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program.
Kanate D; Folk D; Cirone S; Gordon J; Kirlew M; Veale T; Bocking N; Rea S; Kelly L
Can Fam Physician; 2015 Feb; 61(2):160-5. PubMed ID: 25821874
[TBL] [Abstract][Full Text] [Related]
13. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
14. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
Richert T; Johnson B
Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
[TBL] [Abstract][Full Text] [Related]
15. Outcome evaluation of the opioid agonist maintenance treatment in Iran.
Esmaeili HR; Ziaddinni H; Nikravesh MR; Baneshi MR; Nakhaee N
Drug Alcohol Rev; 2014 Mar; 33(2):186-93. PubMed ID: 24428135
[TBL] [Abstract][Full Text] [Related]
16. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of pilot methadone maintenance therapy in Georgia (Caucasus).
Gambashidze N; Sikharulidze Z; Piralishvili G; Gvakharia N
Georgian Med News; 2008; (160-161):25-30. PubMed ID: 18711233
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.
Maas J; Barton G; Maskrey V; Pinto H; Holland R
Drug Alcohol Depend; 2013 Dec; 133(2):494-501. PubMed ID: 23962419
[TBL] [Abstract][Full Text] [Related]
19. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
Fingerhood MI; King VL; Brooner RK; Rastegar DA
Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
[TBL] [Abstract][Full Text] [Related]
20. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
